CP
CPHRF.US Cipher Pharmaceuticals Inc
- Market cap
- USD 253M
- P/E
- 9.0x
- P/B
- 1.77x
- ROE
- 14.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CPHRF.US undervalued?
Graham numberCPHRF.US trades 16.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cipher Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Cipher Pharmaceuticals Inc yet.
Cipher Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of un…
Full company profileCipher Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cipher Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 40.7M | 40.3M | 22.7M | 22.5M | 21.6M | 21.9M | 20.7M | 21.2M | 33.4M | 50.5M | 49.1M |
| Gross Profit | 36.2M | 38.4M | 20.4M | 19.5M | 18.6M | 18.3M | 16.7M | 17.1M | 24.1M | 40.4M | 40.0M |
| Operating Income | -31.8M | 25.2M | 5.33M | 11.7M | 12.2M | 11.8M | 11.1M | 10.3M | 7.85M | 16.9M | 20.7M |
| EBITDA | 4.35M | 26.2M | 6.16M | 12.9M | 13.4M | 12.5M | 12.1M | 11.5M | 11.9M | 24.1M | 26.7M |
| Net Income | -39.1M | 4.40M | 543K | 3.24M | 4.55M | 7.76M | 26.6M | 20.4M | 11.5M | 27.3M | 20.4M |
| EPS | -1.45 | 0.16 | 0.02 | 0.12 | 0.17 | 0.29 | 1.03 | 0.85 | 0.45 | 1.08 | 0.80 |
| Balance Sheet | |||||||||||
| Total Assets | 77.4M | 63.1M | 55.7M | 46.5M | 44.3M | 51.7M | 73.8M | 86.0M | 163M | 157M | 157M |
| Total Liabilities | 59.4M | 40.2M | 30.9M | 18.4M | 11.6M | 12.8M | 9.70M | 5.51M | 60.2M | 30.3M | 19.6M |
| Shareholders' Equity | 18.0M | 22.9M | 24.8M | 28.0M | 32.6M | 38.9M | 64.1M | 80.5M | 102M | 126M | 137M |
| Cash & Short-term Investments | 34.5M | 28.2M | 10.4M | 6.35M | 9.14M | 20.5M | 28.8M | 39.8M | 17.8M | 7.49M | 9.11M |
| Total Debt | 36.4M | 18.1M | 17.6M | 9.57M | 1.85M | 516K | 428K | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.5M | 19.9M | 11.3M | 8.86M | 11.7M | 13.8M | 10.6M | 16.0M | 19.5M | 29.7M | 15.1M |
| Capital Expenditure | 632K | 202K | 6.63M | 1.31M | 760K | 81.0K | 81.0K | 144K | 44.0K | 201K | 1.63M |
| Free Cash Flow | 10.8M | 19.7M | 4.66M | 7.55M | 10.9M | 13.8M | 10.5M | 15.9M | 19.5M | 29.5M | 13.5M |
| Ratios | |||||||||||
| ROE | -217.3% | 19.2% | 2.2% | 11.6% | 13.9% | 19.9% | 41.6% | 25.3% | 11.3% | 21.6% | 14.8% |
| ROA | -50.6% | 7.0% | 1.0% | 7.0% | 10.3% | 15.0% | 36.1% | 23.7% | 7.1% | 17.5% | 13.0% |
| Net Profit Margin | -96.1% | 10.9% | 2.4% | 14.4% | 21.1% | 35.4% | 128.8% | 96.3% | 34.6% | 54.2% | 41.4% |
| Debt to Equity | 2.02x | 0.79x | 0.71x | 0.34x | 0.06x | 0.01x | 0.01x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cipher Pharmaceuticals Inc dividends
Cipher Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Cipher Pharmaceuticals Inc
- Insiders 42.74%
- Institutions 1.32%
- Public & others 55.94%
- Shares outstanding 25.4M
- Free float 14.8M
Cipher Pharmaceuticals Inc company profile
- Company name
- Cipher Pharmaceuticals Inc
- Ticker
- CPHRF.US
- ISIN
- CA17253X1050
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 5750 Explorer Drive, Mississauga, ON, Canada, L4W 0A9
- Phone
- 905 602 5840
- Website
- cipherpharma.com
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.
Cipher Pharmaceuticals Inc management
5- Mr. Craig J. MullInterim CEO & Chairman of the Board
- Mr. Bryan JacobsPresident
- Mr. Ryan MaillingChief Financial Officer
- Mr. Emilio PrestiDirector of Sales & Marketing
- Ms. Shengnan GuoCorporate Controller